

cian supply over the past decade. This is simple arithmetic: an enrolment cut in 1992 would not have been felt until 1998 at the earliest, when those taking the shortest route to licensure entered the workforce.

My paper draws attention to other, more significant policies, such as the decision to increase the ratio of specialists to family physicians trained. This change was not made to accommodate more doctors opting for specialty training or because of insufficient funding, as Scully suggests. Rather, it was an attempt to meet the vague objective of restoring the 50:50 mix of specialists to family physicians, at a time when some provinces had slightly more of the latter.² This policy was implemented without public debate, documented evidence of need or projections of its impact. It led to a precipitous drop in the inflow of new doctors over several years and was the single biggest factor behind Canada's declining physician supply.

I agree with Scully, in principle, that the net loss of Canadian physicians abroad over the past decade represents a heavy burden for our nation. I welcome any attempts by policy-makers to encourage physicians to remain in Canada. However, Canada has lived with the brain drain for over 20 years, and its magnitude has not changed appreciably during the past decade. Hence, the brain drain was not a pivotal factor in the drop in our physician supply. Furthermore, our brain drain has historically been buffered by a "brain gain" from other countries. Yet the entry of foreign medical graduates was drastically curtailed in the 1990s, because of decisions by governments and organized medicine.²

Ultimately, my report was not intended to point the finger at governments, doctors or the academics who supplied the numbers. No one can be expected to predict the future with complete accuracy. Rather, I have offered some feedback to policy-makers on the impact of their actions, both intended and unintended. It is through feedback that we learn from our inevitable mistakes so that we can do a

better job next time. Peltekian is correct in asserting that we need a comprehensive, coordinated framework for health human resource planning. We must monitor trends every year, set plans more frequently, and continually fine-tune our policies on admissions, postgraduate training and foreign graduate intake. We must do a better job of anticipating future demand, identifying more efficient models of care and reducing inappropriate care. Finally, we must start behaving like a nation and engender the kind of cooperation across the provinces that is needed to serve the public.

Benjamin T.B. Chan

Consultant
Canadian Institute for Health
Information
Ottawa, Ont.

References

1. Chan BTB. *From perceived surplus to perceived shortage: What happened to Canada's physician workforce in the 1990s?* Ottawa: Canadian Institute for Health Information; 2002.
2. Cox A, Hoyt-Hallett, cochairs. Report of the National Coordinating Committee on Postgraduate Medical Training to the Conference of Deputy Ministers of Health, 1992 Dec 16.

Restricted access for PPIs not a panacea

We read with interest the findings of Marshall and associates,¹ who found that interventions to reduce the cost to the British Columbia government of 2 drug classes (reference-based pricing for histamine-2 receptor antagonists and restricted access through special authority for proton pump inhibitors [PPIs]) led to substantial savings in the 12-month period after implementation.

In 1992 the Australian government introduced a similar policy of special authority for PPIs to control drug costs. In contrast to the Canadian system, in which prescriptions issued by gastroenterologists were exempt from the policy, in Australia all cases of esophagitis for which PPIs were prescribed and dispensed had to be endoscopically proven, and hence specialists

were not excluded. Despite the restrictions imposed by the policy, Australia experienced a progressive increase in prescriptions for PPIs, and by 1999 PPIs accounted for 34% of antiulcer prescriptions and 51% of government expenditure on antiulcerants.² Concurrently, rates of upper gastrointestinal endoscopy in New South Wales rose by 40%.³ Ultimately, in 2001 the Australian government removed the prescribing restriction on PPIs.

Although the findings of Marshall and associates¹ will be of great interest to administrators in other health care systems struggling with the cost of these drugs, data on other changes in practice, such as referral to gastroenterologists, are needed to more fully assess the overall financial impact of the Canadian strategy.

Anne E. Duggan

Director
Department of Gastroenterology
John Hunter Hospital
Hunter Region, New South Wales,
Australia

Johanna Westbrook

Associate Professor
University of New South Wales
Kensington, New South Wales, Australia

References

1. Marshall JF, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. *CMAJ* 2002;166:1655-62.
2. Westbrook J, McIntosh J, Duggan A. Antiulcerant prescriptions in Australia: a volume, trends and costs: implications for the UK. *BMJ* 2001; 323:1338-9.
3. Westbrook JI. Trends in the utilization of diagnostic upper GI endoscopy in New South Wales, Australia, 1988 to 1998. *Gastrointest Endosc* 2002;55(7):847-53.

[Three of the authors respond:]

We agree that no economic evaluation of drug formulary policy is complete without careful consideration of its effects on resource utilization in other health care sectors. In our article we emphasized the need for more holistic reviews of reference-based pricing and restricted-access policies, with attention to outcomes such as health